Press Release

United States Ovarian Cancer Diagnostics Market to Grow with a CAGR of 5.79% through 2029

Growing incidence and prevalence of ovarian cancer is expected to drive the United States Ovarian Cancer Diagnostics Market in the forecast period 2025-2029


According to TechSci Research report, “United States Ovarian Cancer Diagnostics Market, By Region and Competition, Opportunity, and Forecast, 2019-2029F”, the United States Ovarian Cancer Diagnostics Market stood at USD 284.13 million in 2023 and is anticipated to grow with a CAGR of 5.79% in the forecast period, 2025-2029. Ovarian cancer is a challenging adversary in the world of oncology. Known as the "silent killer" due to its often-asymptomatic early stages, it is crucial to diagnose and treat ovarian cancer as early as possible. The rising incidence of ovarian cancer in the United States is a significant driver for the diagnostics market. According to the American Cancer Society, ovarian cancer ranks fifth in cancer-related deaths among women. As the population ages and risk factors like obesity become more prevalent, the demand for ovarian cancer diagnostics continues to surge. Early diagnosis is the cornerstone of successful treatment, prompting both patients and healthcare providers to prioritize screening and diagnostic tests.

The rapid evolution of diagnostic technologies is another major driver in the United States Ovarian Cancer Diagnostics Market. Traditional methods like ultrasound and blood tests (CA-125) are being complemented and, in some cases, replaced by more advanced approaches. Innovations such as liquid biopsies, which detect cancer-related DNA or proteins in the bloodstream, offer non-invasive and highly sensitive early detection capabilities. The molecular diagnostics and genetic testing have paved the way for personalized treatment plans, tailoring therapies to an individual's genetic makeup. Ovarian cancer presents a formidable challenge in oncology, spurring demand for early detection solutions in the United States. Its asymptomatic early stages drive urgency, given its high mortality rate among women. The evolving landscape of diagnostic technologies is reshaping the market, with advanced methods like liquid biopsies and genetic testing enhancing detection sensitivity and personalized treatment strategies. Heightened awareness campaigns, particularly during Ovarian Cancer Awareness Month in September, bolster screening efforts, especially for high-risk individuals. Collaboration among academia, research institutions, and pharmaceutical firms fuels innovation, advancing diagnostic accuracy and treatment efficacy through clinical trials. As the population ages and risk factors like obesity rise, the need for effective ovarian cancer diagnostics intensifies, underscoring the importance of ongoing advancements and awareness initiatives.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Ovarian Cancer Diagnostics Market.”


The United States Ovarian Cancer Diagnostics Market is segmented into diagnosis type, cancer type, end use, regional distribution, and company. 

Based on cancer type, Epithelial tumors emerged as the dominant segment in the United States market for United States Ovarian Cancer Diagnostics Market in 2023. Epithelial tumors are the dominant subtype among ovarian cancers. These tumors originate from the cells lining the surface of the ovaries and are the most common type, accounting for approximately 90% of cases. Their dominance is attributed to their diverse histological subtypes and aggressive nature, often leading to late-stage diagnosis. The epithelial tumors are associated with various risk factors such as age, genetic mutations, and hormonal factors. Their prevalence underscores the importance of effective screening and diagnostic measures to improve early detection and treatment outcomes in ovarian cancer management.

Based on the End Use, Cancer Diagnostic Centers emerged as the dominant segment in the United States Ovarian Cancer Diagnostics Market in 2023 due to their specialized expertise and comprehensive diagnostic capabilities. These centers house multidisciplinary teams of oncologists, radiologists, pathologists, and other specialists dedicated to cancer diagnosis. Their focused approach enables timely and accurate evaluations of patients with potential ovarian cancer symptoms or risk factors. With early diagnosis being critical for improved outcomes, patients and healthcare providers increasingly rely on Cancer Diagnostic Centers for advanced screening, genetic testing, imaging, and biopsy services, driving their prominence in the market.

Based on region, Mid-West emerged as the dominant player in the United States Ovarian Cancer Diagnostics Market in 2023, holding the largest market share. The Mid-West emerged as the dominant player in the United States Ovarian Cancer Diagnostics Market in 2023 due to several factors. Firstly, the region's extensive network of healthcare facilities, including cancer diagnostic centers and research institutions, provided robust infrastructure for early detection and diagnosis. The Mid-West's proactive approach to healthcare, coupled with high levels of awareness about ovarian cancer and screening initiatives, led to increased demand for diagnostic services. The region's emphasis on precision medicine and collaborative research efforts further strengthened its position in offering advanced diagnostic technologies and personalized treatment options, driving its dominance in the market.


Major companies operating in United States Ovarian Cancer Diagnostics Market are:

  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • AstraZeneca plc
  • Siemens Healthcare GmbH
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc
  • Bio-Rad Technologies Inc
  • Eli Lily and Company


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The United States Ovarian Cancer Diagnostics (NGS) market is poised for significant growth in the coming years. Rising ongoing advancements in diagnostic technologies, the increasing awareness of ovarian cancer and the importance of early detection is bolstering the market growth within United States. With the rise of molecular diagnostics, liquid biopsies, and artificial  ntelligence, the field is becoming increasingly precise and accessible. Government support, research funding, and patient advocacy are further driving progress. The integration of telehealth services and the evolving healthcare landscape are expected to enhance accessibility to diagnostic services” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

United States Ovarian Cancer Diagnostics Market Segmented By Diagnosis Type (Imaging, Blood Test, Biopsy, Others), By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others), By End Use (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others) Region and Competition, Opportunity, and Forecast, 2019-2029F”, has evaluated the future growth potential of United States Ovarian Cancer Diagnostics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Ovarian Cancer Diagnostics Market.



TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]


Relevant News